The week in one idea
Unitree’s post-IPO slide looked like a correction of an irrational debut print, and this week’s coverage largely told it that way. Its disclosure, filed before the stock ever traded, describes something more specific. First-half revenue grew 48.5 percent. The profit line that strips out one-time items fell 19.3 percent, because research and marketing spending grew faster than sales did. Buyers who pushed the stock 629 percent above its IPO price were pricing in years of unusually high growth and strong profitability. The filing instead shows growth decelerating and its defense turning expensive, not a business that stopped working. That gap will matter to more than one stock: Unitree’s repriced multiple is becoming a new mainland reference point for Chinese humanoid and embodied-intelligence listings.
The number that matters
48.5% revenue growth, -19.3% adjusted profit. Unitree’s first-half 2026 results, disclosed August 17.
Why it matters: The market’s opening print valued Unitree 629 percent above its IPO price, leaving little room for growth deceleration and heavier reinvestment. The interim filing shows both: decelerating growth and shrinking adjusted profit, as R&D and marketing costs outrun sales.
What changed
The retreat resumed after a brief pause. Unitree closed at 514.98 yuan on September 18, a month after its August 19 listing, up 2.33 percent that day and briefly described in press coverage as the stock finding a floor. That description did not last: Nikkei Asia’s September 21 report, with retail investors reassessing humanoid robots, put the decline at more than 50 percent from the opening price. By September 23 the stock had slipped further, to around 491 yuan. Against the 1,100-yuan opening print on debut day, that is a decline of about 55 percent and roughly 246 billion yuan of paper value gone, on a share count of 404.5 million unchanged since listing.
The swing to profit is entirely a base effect. Unitree’s net profit attributable to shareholders was 274 million yuan in the first half of 2026, against a loss of 32 million yuan a year earlier. That reversal is more than explained by one item: a 349 million yuan share-based compensation charge, larger than the entire reported swing, tied to an employee-incentive capital injection and booked as non-recurring. Strip non-recurring items from both periods and the picture reverses: adjusted net profit fell to 244 million yuan this year from 302 million yuan, down 19.34 percent. The business did not swing from loss to profit; on the comparable measure, it went from a larger profit to a smaller one.
Growth and margin were already moving before this quarter. Revenue growth has decelerated sharply from 2025’s pace: up 332.64 percent in the first quarter of 2025, down to 68.49 percent in the first quarter of 2026, and to 48.54 percent for the full first half. Unitree’s own filing attributes the shrinking adjusted profit to research spending up 82 million yuan year on year and to marketing spending built around a televised Lunar New Year robot-dance campaign. Gross margin on the humanoid product line, not the company overall, fell from 87.67 percent in 2023, when volumes were still tiny, to 63.18 percent in 2025, as the business scaled into higher-volume, lower-priced models. None of this is new this week. It is the base rate the market is now pricing against.
The repricing sets the next company’s number, not just Unitree’s. An embodied-intelligence investor quoted by Beijing News’s financial desk made the point directly: Unitree’s opening-print valuation, briefly above 400 billion yuan, was never sustainable. As the first humanoid maker to list on a mainland exchange, Unitree gave still-private Chinese humanoid and embodied-intelligence companies a mainland reference multiple that did not exist a month ago.
What it changes
Unitree’s slide is not evidence the humanoid opportunity failed. Revenue is still growing rapidly, and the humanoid line remains highly profitable on gross margin despite the decline from its early, low-volume economics. What changed is the assumption embedded in the opening print: that growth would stay exceptional while margins held. The interim filing instead shows a company spending heavily on research and brand to defend share, in a market where a widely cited industry report puts Chinese humanoid shipments above 40,000 units in the first half alone, a figure other trackers count meaningfully lower, with new entrants arriving either way. That is an ordinary trade-off between margin and market position, not a demand failure, though it prices differently from a company assumed to compound for free.
Model update: Read Unitree’s post-listing volatility as the market recalibrating a growth-and-margin assumption rather than withdrawing conviction in the sector, and expect the next Chinese embodied-intelligence listing to be priced against that recalibrated multiple, not against August’s opening print.
The strongest countercase
A well-informed skeptic would say most of this decline is a genuinely irrational opening print correcting itself, not a reassessment of the business. Unitree priced its IPO around 61 billion yuan; the market’s opening print, on thin float with no daily price limit for five trading days and only intraday halts as a backstop, briefly valued it near 445 billion yuan before settling closer to 200 billion now, making the opening print itself the unusual data point, not this month’s retreat from it. Unitree’s filing describes no material adverse development in the first half, and at around 491 yuan the stock still trades more than three times its offer price. Chinese commentary has called the long-term robotics thesis intact while calling the opening print unsustainable.
Medium confidence: the earnings mechanism is disclosed and consistent across independent outlets, but how much of the price move reflects thin float and sentiment rather than the earnings read cannot be cleanly separated with this week’s evidence.
Since last week
Two forward tests from last ICM weekly remain open with no new evidence. CXMT’s board has not yet disclosed how it will use the roughly 36.8 billion yuan of net IPO proceeds above its original project plan, freed up after the greenshoe’s full exercise, and its third-quarter report is not due until late October. Huawei’s fourth quarter, the test for whether 950DT shipments catch up to price, has not started. Separately, CXMT announced this week that its fifth-generation DRAM platform has entered mass production, narrowing its process gap with the leading global memory makers on metrics like active-area half-pitch, though the announcement names no HBM product built on it.
What we’re watching next
Unitree’s next disclosure. Research and marketing spending growing in line with revenue, rather than faster, would say the reinvestment phase is ending. Another double-digit adjusted-profit decline alongside slower revenue growth would strengthen the case that growth is becoming more expensive.
The next embodied-intelligence listing. A Chinese humanoid or component maker pricing its next raise or IPO below Unitree’s post-retreat multiple would confirm the market has reset the sector’s reference valuation. A comparable multiple would suggest this month’s repricing has not yet reached the private market.
Inside China’s Machine Weekly is research, not investment advice.